The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Real-world effectiveness of Pola-R-CHP versus R-CHOP in older patients with DLBCL in the US
Matthew Matasar, MD, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, discusses the real-world effectiveness of polatuzumab vedotin (Pola) plus rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in older patients with diffuse large B-cell lymphoma (DLBCL) in the United States. Dr Matasar highlights that the benefits of the Pola-R-CHP regimen, established in the POLARIX clinical trial (NCT03274492), appear to translate to the real-world setting. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
